Immune Globulin Subcutaneous (Human) 20%: In Primary Immunodeficiency Disorders

Author： McCormack Paul L.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.72, Iss.8, 2012-05, pp. : 1087-1097

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency

By Wasserman Richard L.  

Clinical Pharmacokinetics, Vol. 50, Iss. 6, 2011-06 ,pp. : 405-414

Adis International

Access to resources Recommend Favorite

Immune globulin: Haemolysis: 20 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1276, 2009-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Immune globulin: Neuromuscular disorders in an elderly patient: case report

By  

Reactions Weekly, Vol. 1, Iss. 1156, 2007-01 ,pp. : 14-15

Adis International

Access to resources Recommend Favorite

Immune globulin/omalizumab: Skin disorders and hypotension: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1429, 2012-01 ,pp. : 24-24

Adis International

Access to resources Recommend Favorite

Immune globulin: Osmotic kidney disorders leading to renal failure following administration of a maltose-based formulation: case report

By  

Reactions Weekly, Vol. 1, Iss. 1101, 2006-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite